Announced Sat, 24 Jan · 12:06 IST

Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve 1.approval of Unaudited ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Sandu Pharmaceuticals has informed BSE that its Board of Directors will meet on Friday, 06 February 2026 at 4:00 p.m. at the Corporate Office in Chembur, Mumbai. The key agenda item is to approve the Standalone Unaudited Financial Results for the quarter and period ended 31 December 2025 (Q3 FY26). Additionally, the trading window for dealing in the company's securities has been closed for directors, officers, and designated employees from 01 January 2026 until 48 hours after the results are publicly announced, in line with insider trading regulations.

Likely market impact

This is a routine regulatory filing ahead of the Q3 FY26 earnings announcement on 06 February 2026. No new financial information is disclosed yet — investors should wait for the actual results to assess performance. The closed trading window signals that results could be material to the stock.